Navigation Links
Immune Design Corp. Appoints Guy F. Cipriani as Chief Business Officer
Date:10/18/2011

SEATTLE, Oct. 18, 2011 /PRNewswire/ -- Immune Design Corp. (IDC) announced today that Guy F. Cipriani, MBA will be joining the company as its new Chief Business Officer.  In the position, Mr. Cipriani will leverage more than 12 years of pharmaceutical and biotechnology industry experience to lead strategy and business development activities for the company's rapidly advancing pipeline of novel therapeutic vaccines and immunotherapies for infectious diseases, cancer and allergy.

(Logo:  http://photos.prnewswire.com/prnh/20111018/SF88252LOGO)

Most recently, he was Vice President of Business Development and a member of senior management at Cardiome Pharma Corp. in Vancouver, B.C. Canada.  Prior to Cardiome, Mr. Cipriani served as Director of Business Development for TransForm Pharmaceuticals, Inc., a biotechnology company based in Lexington, MA, that was acquired by Johnson and Johnson in April 2005. He also spent 5 years in Corporate Business Development at Eli Lilly and Company in Indianapolis, IN, and previously as a management consultant with Accenture in Chicago, IL.  Mr. Cipriani received his MBA from the Kellogg School of Management at Northwestern University and holds a B.S.E.E., High Honors from Rochester Institute of Technology.

"We are pleased to welcome Guy to our senior management team, as he is an extraordinary individual with great experience.  His demonstrated success in both biotechnology and pharmaceutical companies will be of significant value to IDC as we pursue new collaborations around our two platforms and broad strategic partnerships," said Carlos V. Paya. MD, Ph.D., Chief Executive Officer of IDC.

Mr. Cipriani commented, "I am excited to join an organization with such talented scientists and promising technologies.  I believe that IDC's platforms have tremendous partnering potential and that they can be leveraged in transactions that allow the company to advance aggressively.  I look forward to playing a key role on the senior management team as we take the company forward."

About Immune Design Corp.

Immune Design Corp. is a privately held, clinical-stage biotechnology company based in Seattle, Washington and formed in 2008 to bring together some of the world's leaders in the field of molecular immunology to develop vaccines for the treatment and prevention of infectious and malignant disease.  The company employs advanced and leading edge methods to precisely control the activation and context of antigen presentation by dendritic cells in order to shape the desired adaptive immune response.  This goal is accomplished through the application of two proprietary technology platforms that activate the immune system by distinct mechanisms.

Additional information can be found on the company's website at www.immunedesign.com.

Contact Media:
Cassie Ostrander 206-826-7901 or media@immunedesign.com


'/>"/>
SOURCE Immune Design Corp.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Alcohol-related behavior changes -- blame your immune system
2. Immune Deficiency Foundation Launches Free Accredited Course for Nurses About Primary Immunodeficiency and Immunoglobulin Therapy
3. New HIV vaccine approach targets desirable immune cells
4. David H. Murdock Research Institute Assumes Control of the Immune Tolerance Institute and Establishes a State of the Art Human Immune Monitoring Laboratory for Biomarker Discovery and Development
5. Inovio Pharmaceuticals Reports Long-Term Immune Responses from Therapeutic Cervical Dysplasia and Cancer DNA Vaccine
6. UCLA scientists discover new way to wake up the immune system using nano vaults to deliver drugs
7. Amgen and Xencor Enter Option Deal to Co-Develop Xencors Novel Antibody for Autoimmune Diseases
8. NIH scientists show how anthrax bacteria impair immune response
9. Immune Design Grants Adjuvant License to MedImmune
10. Adaptive TCR Launches the immunoSEQâ„¢ Product Line - Visualizing the Immune System With Next-Generation Sequencing.
11. Major disease-vector mosquito reveals the secrets of its immune system
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
(Date:6/23/2016)... Ky. , June 23, 2016 ... two Phase 1 clinical trials of its complement ... placebo-controlled, single and multiple ascending dose studies designed ... pharmacodynamics (PD) of subcutaneous injection in healthy adult ... subcutaneously (SC) either as a single dose (ranging ...
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory Compliance Associates® Inc. (RCA), ... free webinar on Performing Quality Investigations: Getting to Root Cause. ... no charge. , Incomplete investigations are still a major concern to the Regulatory ...
Breaking Biology Technology:
(Date:6/7/2016)... , June 7, 2016  Syngrafii Inc. ... a business relationship that includes integrating Syngrafii,s patented ... branch project. This collaboration will result in greater ... the credit union, while maintaining existing document workflow ... http://photos.prnewswire.com/prnh/20160606/375871LOGO ...
(Date:6/1/2016)... June 1, 2016 Favorable Government ... Administration and Criminal Identification to Boost Global Biometrics System ... released TechSci Research report, " Global Biometrics Market ... Forecast and Opportunities, 2011 - 2021", the global biometrics ... 2021, on account of growing security concerns across various ...
(Date:5/9/2016)... 2016 Elevay is currently known ... freedom for high net worth professionals seeking travel for ... connected world, there is still no substitute for a ... sealing your deal with a firm handshake. This is ... advantage of citizenship via investment programs like those offered ...
Breaking Biology News(10 mins):